Skip to content
This is the second in a series of Bio.News articles looking at the need for pharmacy benefit manager reform through the lens of the […]
Putting patients first: Unchecked step therapy puts PBM profits ahead of patient care Read More »
This is the first in a series of Bio.News articles looking at the need for pharmacy benefit manager (PBM) reform through the lens of
Insurers and pharmacy benefit managers (PBMs) in search of profits are preventing patients from getting the drugs they need, according to the latest episode
How utilization management blocks patient access Read More »
The Biotechnology Innovation Organization (BIO) has once again requested that the Centers for Medicare & Medicaid Services (CMS) take steps to protect patient access,
CMS must address Part D plan abuse of IRA provisions designed to protect patient access Read More »
Despite frequent criticism of the Federal Trade Commission (FTC), the Conservative Political Action Conference (CPAC) has announced its support for FTC efforts to rein in pharmacy
CPAC supports FTC action against pharmacy benefit managers Read More »
October is the scariest time of year. Young goblins walk the streets demanding treats, local haunted houses are packed full of fright-chasing teens, and
Open enrollment can be a ‘House of Horrors’: 4 monsters for patients to beware Read More »
The 340B program grew by 24% in 2023, according to new figures from the government’s Health Resources and Services Administration. Sales at discounted prices
Skyrocketing 340B program spending must prompt more hospital accountability Read More »
A family battling rare disease, a biopharma startup they’re assisting, and an organization seeking congressional support for new rare disease drugs share their journeys
A family, a firm, and a foundation fighting rare disease join BIO’s podcast Read More »
The search for safer, effective replacements for opioids is a critical public health priority, but that effort is being undermined by the Inflation Reduction
Development of non-opioid pain medicines threated by IRA’s ‘pill penalty’ Read More »
The Inflation Reduction Act (IRA) has been top of mind for many in the biotech industry. The first round of price negotiations and the
BIF 2024: ‘The IRA really disrupted how we think’ Read More »
